GlassScriptPhysician profile
Vangel Orencia Quilon
NPI 1679090492
$10,228.80
in general payments reported to CMS, 2019-2025
55 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,460 · 2022: $3,475 · 2023: $2,395 · 2024: $1,762 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,089 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,089.32 |
| Education | $205.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $2,149.99 | 2022 | |
| Abbvie INC. | $1,210.48 | 2021-2025 | |
| Biogen, INC. | $581.71 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Teva Pharmaceuticals USA, INC. | $563.22 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lundbeck LLC | $495.20 | 2022-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $419.26 | 2021 | |
| Pfizer INC. | $345.29 | 2022-2025 | |
| Sage Therapeutics, LLC | $292.50 | 2023 | |
| Inspire Medical Systems, INC. | $245.43 | 2022-2024 | Inspire |
| Livanova USA, INC. | $236.35 | 2021 | |
| Ucb, INC. | $210.26 | 2023-2025 | Briviact, Rystiggo |
| Eisai INC. | $204.13 | 2021-2025 | |
| Harmony Biosciences LLC | $195.44 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $190.48 | 2023-2025 | Rexulti, Nuedexta |
| Sk Life Science, INC. | $190.10 | 2022-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $184.32 | 2021 | |
| Amgen INC. | $146.51 | 2021-2025 | Aimovig, Uplizna |
| Alexion Pharmaceuticals, INC. | $145.03 | 2023-2025 | Ultomiris |
| Lilly USA, LLC | $138.58 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Corium, LLC | $137.41 | 2022-2023 | Adlarity, Adlarity |
| Emd Serono, INC. | $132.45 | 2024 | |
| Neurelis, INC. | $122.81 | 2022-2025 | Valtoco |
| Mylan Specialty L.P. | $120.68 | 2022 | |
| Novo Nordisk INC | $106.01 | 2023 | |
| Genentech USA, INC. | $104.73 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $98.32 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $93.95 | 2023-2024 | Aptiom |
| Paratek Pharmaceuticals, INC. | $86.78 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $86.11 | 2022-2023 | Belsomra |
| Spark Therapeutics, INC. | $78.90 | 2022 | |
| Grifols USA, LLC | $78.78 | 2021-2024 | Gamunex-C |
| Allergan, INC. | $74.79 | 2021 | |
| Axsome Therapeutics, INC. | $65.21 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $64.77 | 2021-2024 | |
| Impel Pharmaceuticals INC. | $62.07 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $53.74 | 2022-2024 | Rytary |
| Janssen Pharmaceuticals, INC | $52.01 | 2022-2025 | |
| Banner Life Sciences, LLC | $49.18 | 2022-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $48.12 | 2024 | Lumryz |
| Idorsia Pharmaceuticals US INC | $47.40 | 2022-2024 | Quviviq |
| Kyowa Kirin, INC. | $42.46 | 2022 | |
| Mdd US Operations, LLC | $34.99 | 2023 | Gocovri |
| Argenx US, INC. | $23.28 | 2023 | Vyvgart Hytrulo |
| Celgene Corporation | $21.83 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.46 | 2025 | Qelbree |
| Acorda Therapeutics, INC | $21.11 | 2022 | |
| Nevro Corp. | $20.16 | 2023 | Senza |
| Csl Behring | $19.78 | 2022 | |
| Cycle Pharmaceuticals INC | $18.87 | 2025 | Tascenso Odt, Bafiertam |
| Kedrion Biopharma, INC. | $18.19 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Tanabe Pharma America, INC. | $17.96 | 2022 | |
| Averitas Pharma INC. | $17.09 | 2025 | Qutenza |
| Boston Scientific Corporation | $15.75 | 2023 | |
| Neurocrine Biosciences, INC. | $14.00 | 2024 | Ingrezza |
| Upsher-Smith Laboratories LLC | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vangel Quilon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.